01—Abstract
Summary
Summary of the 8-K filed November 3, 2025. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories reported third quarter 2025 results on November 3, 2025, with revenue of $1,105 milliona, up 13% as reported and 12% organic.
Growth was led by Companion Animal Group (CAG), which rose 14%b as reported and 12% organic, and Livestock, Poultry and Dairy (LPD), which rose 17% as reported and 14% organic. CAG Diagnostics recurring revenue grew 11% as reported and 10% organic, with international regions up 18% reported and U.S. up 8%. Growth was supported by strong IDEXX VetLab consumables (+18% reported) and over 1,700 IDEXX inVue Dx placements, which drove capital instrument revenue up 74%.
Profitability improved meaningfully. Diluted EPS was $3.40c, up 21% as reported and 15% on a comparable basis, which excludes $0.17 of share-based compensation tax benefits and $0.02 of currency benefit. Gross margin rose 70 basis points to 61.8%, and operating margin expanded 100 basis points to 32.1% (120 basis points comparable).
Operating expenses rose 12%, reflecting commercial, R&D, and incentive investments. Free cash flow for the quarter was $371 milliond, versus $192 million a year earlier. Management raised full-year 2025 guidance across the board.
Revenue is now expected at $4,270–$4,300 million (9.6%–10.3% reported growth), EPS at $12.81–$13.01 (up $0.33 at the midpoint), and operating margin at 31.6%–31.8%. Investors should note that the EPS raise includes some non-operational items, including tax and share-count effects, and that the Company's share repurchases of about $979 million year-to-date have been funded partly by a higher credit facility balance of $455 million.
02—Key points
Key Highlights
- Q3 2025 revenue of $1,105M rose 13% as reported and 12% organic, with CAG up 14% and LPD up 17%.
- Diluted EPS of $3.40 rose 21% as reported and 15% comparable; comparable EPS excludes $0.17 of share-based compensation tax benefits.
- Operating margin reached 32.1%, up 100 bps as reported and 120 bps comparable, despite a 12% rise in operating expenses.
- Full-year 2025 revenue guidance raised to $4,270M–$4,300M; EPS guidance raised to $12.81–$13.01, a $0.33 increase at midpoint.
- CAG Diagnostics recurring revenue grew 11% reported and 10% organic, with international up 18% and U.S. up 8%; over 1,700 inVue Dx placements drove capital instrument revenue up 74%.
- Free cash flow for the nine months was $731M versus $575M a year earlier, and the Company repurchased roughly $979M of stock year-to-date.
- Rapid assay products declined 4% as reported, reflecting volume shifts tied to the Catalyst Pancreatic Lipase test launch.
03—Questions
Frequently Asked Questions
What drove IDEXX's strong third-quarter revenue growth?
Growth was broad-based, led by IDEXX VetLab consumables (up 18% reported, 16% organic), strong capital instrument placements (up 74%) driven by over 1,700 inVue Dx placements, and international CAG Diagnostics recurring revenue (up 18% reported). U.S. CAG Diagnostics recurring revenue grew 8%, aided by higher diagnostic frequency and easing clinical visit pressures.
How much of the EPS increase was operational versus non-operational?
Reported EPS grew 21%, but comparable EPS grew 15% to $3.22 after excluding $0.17 of share-based compensation tax benefits and $0.02 of currency benefit. Investors should focus on the 15% comparable figure when judging operating performance, since the share-based compensation benefit is timing-dependent and may not recur at the same level.
Why did IDEXX raise its full-year guidance, and how much was operational?
The $0.33 EPS raise at midpoint included about $0.22 from operational performance, about $0.04 from a lower effective tax rate (net of U.S. tax law impacts), and about $0.07 from updated interest expense, share count, and FX estimates. Revenue guidance rose about 1% at midpoint, reflecting stronger CAG Diagnostics recurring revenue and higher inVue Dx placement expectations.
Are there any risks or concerns in the quarter?
Operating expenses grew 12% as reported, outpacing revenue growth in dollar terms, reflecting investments in commercial resources and R&D. Rapid assay products declined 4% as reported due to the Catalyst Pancreatic Lipase launch shifting testing across modalities. Share repurchases and a $455M credit facility balance also increased leverage, and the Company's cash balance fell to $208M from $288M at year-end 2024.
04—Continue